{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:19:42Z","timestamp":1791062382464,"version":"4.1.0"},"reference-count":48,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006893","type":"journal-article","created":{"date-parts":[[2008,2,5]],"date-time":"2008-02-05T21:12:31Z","timestamp":1202245951000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease"],"prefix":"10.1002","author":[{"given":"Brian W","family":"Behm","sequence":"first","affiliation":[{"name":"University of Virginia Health Systems; UVA Digestive Health Center of Excellence; Box 800708 Charlottesville VA USA 22908"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Bickston","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases; Virginia Commonwealth University Health System Box 980341 Richmond VA USA 23298"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD006893-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD006893-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2036.2006.02791.x","article-title":"CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Feagan","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"9317","key":"10.1002\/14651858.CD006893-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006893-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD006893-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/gast.2001.24042","article-title":"An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial","volume":"120","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD006893-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2003.035253","article-title":"CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial","volume":"53","author":"Sandborn","year":"2004","journal-title":"Gut"},{"issue":"9","key":"10.1002\/14651858.CD006893-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"9","key":"10.1002\/14651858.CD006893-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD006893-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1002\/14651858.CD006893-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial","volume":"116","author":"D'haens","year":"1999","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD006893-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/j.1572-0241.2003.07674.x","article-title":"The effects of infliximab maintenance therapy on health-related quality of life","volume":"98","author":"Feagan","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1002\/14651858.CD006893-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1185\/030079905X65457","article-title":"Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease","volume":"21","author":"Geboes","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1002\/14651858.CD006893-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD006893-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD006893-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD006893-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD006893-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1002\/14651858.CD006893-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD006893-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest Endosc"},{"issue":"7","key":"10.1002\/14651858.CD006893-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cgh.2006.04.022","article-title":"Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Rutgeerts","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1002\/14651858.CD006893-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD006893-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1002\/14651858.CD006893-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD006893-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"issue":"9051","key":"10.1002\/14651858.CD006893-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","article-title":"Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease","volume":"349","author":"Stack","year":"1997","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD006893-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"issue":"11-12","key":"10.1002\/14651858.CD006893-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2036.2004.02285.x","article-title":"Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study","volume":"20","author":"Winter","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006893-BIB0028|cit28","first-page":"A505","article-title":"Re-induction and maintenance therapy wtih subcutaneous certolizumab pegol in patients with Crohn's disease following treatment failure: PRECiSE 4 results.","volume":"132","author":"Sandborn","year":"2007","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006893-BIB0029|cit29","first-page":"A503","article-title":"Long-term treatment with certolizumab pegol for up to 18 months in patients with active Crohn's disease: PRECiSE 3 efficacy results.","volume":"132","author":"Schreiber","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD006893-BIB0030|cit30","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003574.pub2","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","author":"Akobeng","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"19","key":"10.1002\/14651858.CD006893-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD006893-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD006893-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1001\/jama.296.18.2202","article-title":"Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis","volume":"296","author":"Callegari","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD006893-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archderm.143.3.405","article-title":"What are the risks of serious infections and malignancies for patients treated with anti-tumor necrosis factor antibodies?","volume":"143","author":"Corona","year":"2007","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1002\/14651858.CD006893-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gut.2004.045294","article-title":"Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery","volume":"54","author":"Cosnes","year":"2005","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD006893-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1002\/14651858.CD006893-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD006893-BIB0038|cit38","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005","author":"Higgins","year":"2005"},{"issue":"1","key":"10.1002\/14651858.CD006893-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"7","key":"10.1002\/14651858.CD006893-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/clinchem\/47.7.1297","article-title":"Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR","volume":"47","author":"Komatsu","year":"2001","journal-title":"Clin Chem"},{"issue":"5","key":"10.1002\/14651858.CD006893-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006893-BIB0042|cit42","first-page":"A178","article-title":"Safety of infliximab and other Crohn's disease therapies -- TREAT registry data with nearly 20,000 patient-years of follow up","volume":"132","author":"Lichtenstein","year":"2007","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD006893-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.296.18.2201-b","article-title":"Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis","volume":"296","author":"Okada","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD006893-BIB0044|cit44","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000067","article-title":"Azathioprine for maintenance of remission of Crohn's disease","author":"Pearson","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006893-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/gut.39.5.684","article-title":"Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease","volume":"39","author":"Reimund","year":"1996","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD006893-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7326\/ACPJC-2006-145-3-065","article-title":"Review: anti-tumor necrosis factor antibody therapy for rheumatoid arthritis increases risk for serious infection and malignancy","volume":"145","author":"Shoor","year":"2006","journal-title":"ACP J Club"},{"issue":"5","key":"10.1002\/14651858.CD006893-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1053\/gast.2001.29035","article-title":"Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease","volume":"121","author":"Deventer","year":"2001","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD006893-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"Dullemen","year":"1995","journal-title":"Gastroenterology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T03:53:13Z","timestamp":1684209193000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006893"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":48,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006893","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,23]]}}}